{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:20:44Z","timestamp":1792614044352,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10875-017-0421-7","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T19:45:22Z","timestamp":1501098322000},"page":"582-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Long-Term Outcome of Adenosine Deaminase-Deficient Patients\u2014a Single-Center Experience"],"prefix":"10.1007","volume":"37","author":[{"given":"Ori","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy Hong-Diep","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Huy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelle R.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Grunebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"issue":"6","key":"421_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/ACI.0000000000000006","volume":"13","author":"E Grunebaum","year":"2013","unstructured":"Grunebaum E, Cohen A, Roifman CM. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol. 2013;13(6):630\u20138. doi:10.1097\/ACI.0000000000000006.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"421_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pediatrneurol.2007.03.011","volume":"37","author":"Y Nofech-Mozes","year":"2007","unstructured":"Nofech-Mozes Y, Blaser SI, Kobayashi J, Grunebaum E, Roifman CM. Neurologic abnormalities in patients with adenosine deaminase deficiency. Pediatr Neurol. 2007;37(3):218\u201321.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"421_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00247-012-2564-2","volume":"43","author":"D Manson","year":"2013","unstructured":"Manson D, Diamond L, Oudjhane K, Hussain FB, Roifman C, Grunebaum E. Characteristic scapular and rib changes on chest radiographs of children with ADA-deficiency SCIDS in the first year of life. Pediatr Radiol. 2013 Mar;43(5):589\u201392.","journal-title":"Pediatr Radiol"},{"issue":"15","key":"421_CR4","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1182\/blood-2009-03-209221","volume":"114","author":"AV Sauer","year":"2009","unstructured":"Sauer AV, Mrak E, Hernandez RJ, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL\/OPG imbalance and osteoblast insufficiency. Blood. 2009;114(15):3216\u201326. doi:10.1182\/blood-2009-03-209221.","journal-title":"Blood"},{"issue":"4","key":"421_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.14785\/lpsn-2015-0010","volume":"2","author":"A Pham-Huy","year":"2015","unstructured":"Pham-Huy A, Hong-Diep Kim V, Nizalik E, Weiler G, Vethamuthu J, Grunebaum E. Atypical hemolytic-uremic syndrome in a patients with adenosine deaminase deficiency. LymphoSign Journal. 2015;2(4):195\u20139. doi:10.14785\/lpsn-2015-0010.","journal-title":"LymphoSign Journal"},{"issue":"21","key":"421_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJM199605233342104","volume":"334","author":"ME Bollinger","year":"1996","unstructured":"Bollinger ME, Arredondo-Vega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. New Engl J Med. 1996;334(21):1367\u201371. doi:10.1056\/NEJM199605233342104.","journal-title":"New Engl J Med"},{"issue":"6","key":"421_CR7","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jaci.2012.02.003","volume":"129","author":"E Grunebaum","year":"2012","unstructured":"Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol. 2012;129(6):1588\u201393. doi:10.1016\/j.jaci.2012.02.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"421_CR8","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","volume":"114","author":"HB Gaspar","year":"2009","unstructured":"Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524\u201332. doi:10.1182\/blood-2009-06-189209.","journal-title":"Blood"},{"issue":"17","key":"421_CR9","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","volume":"120","author":"A Hassan","year":"2012","unstructured":"Hassan A, Booth C, Brightwell A, Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615\u20133624; quiz 3626. doi:10.1182\/blood-2011-12-396879.","journal-title":"Blood"},{"issue":"2","key":"421_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/humu.1380050202","volume":"5","author":"MS Hershfield","year":"1995","unstructured":"Hershfield MS. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat. 1995;5(2):107\u201312. doi:10.1002\/humu.1380050202.","journal-title":"Hum Mutat"},{"issue":"2","key":"421_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2006.12.009","volume":"123","author":"C Booth","year":"2007","unstructured":"Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop. Clin Immunol (Orlando, Fla.). 2007;123(2):139\u201347.","journal-title":"Clin Immunol (Orlando, Fla.)"},{"issue":"5","key":"421_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa0805817","volume":"360","author":"A Aiuti","year":"2009","unstructured":"Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New Engl J Med. 2009;360(5):447\u201358. doi:10.1056\/NEJMoa0805817.","journal-title":"New Engl J Med"},{"issue":"97","key":"421_CR13","doi-asserted-by":"publisher","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","volume":"3","author":"HB Gaspar","year":"2011","unstructured":"Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Trans Med. 2011;3(97):97ra80. doi:10.1126\/scitranslmed.3002716.","journal-title":"Sci Trans Med"},{"issue":"4","key":"421_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10875-017-0373-y","volume":"37","author":"DB Kohn","year":"2017","unstructured":"Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017 May;37(4):351\u20136. doi:10.1007\/s10875-017-0373-y.","journal-title":"J Clin Immunol"},{"issue":"7","key":"421_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM199902183400703","volume":"340","author":"RH Buckley","year":"1999","unstructured":"Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999 Feb 18;340(7):508\u201316.","journal-title":"N Engl J Med"},{"issue":"9357","key":"421_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0140-6736(03)12513-5","volume":"361","author":"C Antoine","year":"2003","unstructured":"Antoine C, M\u00fcller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361(9357):553\u201360.","journal-title":"Lancet"},{"issue":"3","key":"421_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jaci.2013.12.1043","volume":"133","author":"I Brigida","year":"2014","unstructured":"Brigida I, Sauer AV, Ferrua F, Giannelli S, Scaramuzza S, Pistoia V, et al. B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. J Allergy Clin Immunol. 2014;133(3):799\u2013806.e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"421_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s10875-015-0191-z","volume":"35","author":"R Baffelli","year":"2015","unstructured":"Baffelli R, Notarangelo LD, Imberti L, et al. Diagnosis, treatment and long-term follow up of patients with ADA deficiency: a single-center experience. J Clin Immunol. 2015;35(7):624\u201337. doi:10.1007\/s10875-015-0191-z.","journal-title":"J Clin Immunol"},{"issue":"2","key":"421_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clim.2015.06.011","volume":"161","author":"Y Nakazawa","year":"2015","unstructured":"Nakazawa Y, Kawai T, Uchiyama T, Goto F, Watanabe N, Maekawa T, et al. Effects of enzyme replacement therapy on immune function in ADA deficiency patient. Clin Immunol. 2015 Dec;161(2):391\u20133.","journal-title":"Clin Immunol"},{"issue":"1","key":"421_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1067\/mpd.2001.115023","volume":"139","author":"MH Rogers","year":"2001","unstructured":"Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr. 2001;139(1):44\u201350.","journal-title":"J Pediatr"},{"issue":"5","key":"421_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0022-3476(76)80793-7","volume":"89","author":"SD Cederbaum","year":"1976","unstructured":"Cederbaum SD, Kaitila I, Rimoin DL, Stiehm ER. The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency. J Pediatr. 1976;89(5):737\u201342.","journal-title":"J Pediatr"},{"key":"421_CR22","first-page":"349","volume":"3","author":"C Booth","year":"2009","unstructured":"Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biol Targets Ther. 2009;3:349\u201358.","journal-title":"Biol Targets Ther"},{"issue":"1","key":"421_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128(1):45\u201354.","journal-title":"Blood"},{"issue":"5","key":"421_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jama.295.5.508","volume":"295","author":"E Grunebaum","year":"2006","unstructured":"Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295(5):508\u201318.","journal-title":"JAMA"},{"key":"421_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-3148.2006.00694_52.x","volume":"16","author":"A Mohamoud","year":"2006","unstructured":"Mohamoud A. Characteristics of Hla class I and class II antigens of the Somali population. Transfus Med. 2006;16:47. (P52)","journal-title":"Transfus Med"},{"issue":"1","key":"421_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jpeds.2007.03.059","volume":"151","author":"M Husain","year":"2007","unstructured":"Husain M, Grunebaum E, Naqvi A, Atkinson A, Ngan BY, Aiuti A, et al. Burkitt\u2019s lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr. 2007;151(1):93\u20135.","journal-title":"J Pediatr"},{"issue":"2","key":"421_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","volume":"117","author":"B Chan","year":"2005","unstructured":"Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133\u201343.","journal-title":"Clin Immunol"},{"issue":"2","key":"421_CR28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0022-3565(24)29400-3","volume":"298","author":"H Zhong","year":"2001","unstructured":"Zhong H, Chunn JL, Volmer JB, Fozard JR, Blackburn MR. Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice. J Pharmacol Exp Ther. 2001;298(2):433\u201340.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"421_CR29","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.4049\/jimmunol.167.8.4676","volume":"167","author":"JL Chunn","year":"2001","unstructured":"Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR. Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol (Baltimore, Md.: 1950). 2001;167(8):4676\u201385.","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"issue":"4","key":"421_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jaci.2009.07.003","volume":"124","author":"R Somech","year":"2009","unstructured":"Somech R, Lai YH, Grunebaum E, Le Saux N, Cutz E, Roifman CM. Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency. J Allergy Clin Immunol. 2009 Oct;124(4):848\u201350. doi:10.1016\/j.jaci.2009.07.003.","journal-title":"J Allergy Clin Immunol"},{"key":"421_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-015-0365-z","volume":"10","author":"HD Komarow","year":"2015","unstructured":"Komarow HD, Sokolic R, Hershfield MS, Kohn DB, Young M, Metcalfe DD, et al. Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. Orphanet J Rare Dis. 2015;10:159. doi:10.1186\/s13023-015-0365-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"421_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.Jpeds.2003.10.055","volume":"144","author":"W Albuquerque","year":"2004","unstructured":"Albuquerque W, Gaspar HB. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr. 2004;144(2):278\u201380. doi:10.1016\/j.Jpeds.2003.10.055.","journal-title":"J Pediatr"},{"key":"421_CR33","doi-asserted-by":"publisher","first-page":"40136","DOI":"10.1038\/srep40136","volume":"7","author":"AV Sauer","year":"2017","unstructured":"Sauer AV, Hernandez RJ, Fumagalli F, Bianchi V, Poliani PL, Dallatomasina C, et al. Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. Sci Rep. 2017 Jan 11;7:40136. doi:10.1038\/srep40136.","journal-title":"Sci Rep"},{"key":"421_CR34","doi-asserted-by":"crossref","unstructured":"Tamura, R., Ohta, H., Satoh, Y., Nonoyama, S., Nishida, Y., & Nibuya, M. (2016). Neuroprotective effects of adenosine deaminase in the striatum. J Cereb Blood Flow Metab","DOI":"10.1177\/0271678X15625077"},{"issue":"5","key":"421_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","volume":"22","author":"H Tran","year":"2008","unstructured":"Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008 Sep;22(5):261\u201381.","journal-title":"Blood Rev"},{"key":"421_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1542\/peds.2005-1068","volume":"116","author":"D Kaufman","year":"2005","unstructured":"Kaufman D, Hershfield M, Bocchini J, Moissidis I, Jeroudi M, Bahna S. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. Pediatrics. 2005;116:876\u20139.","journal-title":"Pediatrics"},{"issue":"6","key":"421_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00383-002-0827-y","volume":"19","author":"D Carroll","year":"2003","unstructured":"Carroll D, Ramani P, Lander AD. Giant-cell fibroblastoma in a patient with a bone-marrow transplant. Pediatr Surg Int. 2003;19(6):495\u20136. doi:10.1007\/s00383-002-0827-y.","journal-title":"Pediatr Surg Int"},{"key":"421_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fphar.2015.00184","volume":"6","author":"H Lei","year":"2015","unstructured":"Lei H, Schmidt-Bleek K, Dienelt A, Reinke P, Volk HD. Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners. Front Pharmacol. 2015;6:184. doi:10.3389\/fphar.2015.00184.","journal-title":"Front Pharmacol"},{"issue":"3","key":"421_CR39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/stem.2280","volume":"34","author":"Erja Kerkel\u00e4","year":"2016","unstructured":"Kerkela E, Laitinen A, Rabina J, et al. Adenosinergic immunosuppression by human mesenchymal stromal cells (MSCs) requires co-operation with T cells. Stem Cells (Dayton, Ohio). 2016; doi:10.1002\/stem.2280.","journal-title":"STEM CELLS"},{"issue":"1","key":"421_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.imbio.2016.01.013","volume":"222","author":"PJ Schuler","year":"2017","unstructured":"Schuler PJ, Westerkamp AM, Kansy BA, et al. Adenosine metabolism of human mesenchymal stromal cells isolated from patients with head and neck squamous cell carcinoma. Immunobiology. 2017;222(1):66\u201374.","journal-title":"Immunobiology"},{"issue":"11","key":"421_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/BF01957930","volume":"151","author":"LD Notarangelo","year":"1992","unstructured":"Notarangelo LD, Stoppoloni G, Toraldo R, et al. Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur J Pediatr. 1992;151(11):811\u20134.","journal-title":"Eur J Pediatr"},{"issue":"8","key":"421_CR42","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood.V89.8.2849","volume":"89","author":"H Ozsahin","year":"1997","unstructured":"Ozsahin H, Arredondo-Vega FX, Santisteban I, Hershfield MS, et al. Adenosine deaminase deficiency in adults. Blood. 1997;89(8):2849\u201355.","journal-title":"Blood"},{"issue":"5","key":"421_CR43","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jaci.2009.08.041","volume":"124","author":"NC Patel","year":"2009","unstructured":"Patel NC, Chinen J, Rosenblatt HM, et al. Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol. 2009;124(5):1062\u20139.e1-4. doi:10.1016\/j.jaci.2009.08.041.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"421_CR44","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2011-01-329359","volume":"118","author":"R Sokolic","year":"2011","unstructured":"Sokolic R, Maric I, Kesserwan C, Garabedian E, Hanson IC, Dodds M, et al. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood. 2011;118(10):2688\u201394. doi:10.1182\/blood-2011-01-329359. Erratum in: Blood. 2014 Mar 13;123(11):1767","journal-title":"Blood"},{"issue":"2","key":"421_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.192.2.159","volume":"192","author":"MR Blackburn","year":"2000","unstructured":"Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med. 2000;192(2):159\u201370.","journal-title":"J Exp Med"},{"issue":"5","key":"421_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11882-016-0615-8","volume":"16","author":"CY Kuo","year":"2016","unstructured":"Kuo CY, Kohn DB. Gene therapy for the treatment of primary immune deficiencies. Curr Allergy Asthma Rep. 2016;16(5):39.","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-017-0421-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-017-0421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-017-0421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:14:31Z","timestamp":1750788871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-017-0421-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1007\/s10875-017-0421-7","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]},"assertion":[{"value":"1 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AA is the principal investigator of the ADA-SCID gene therapy clinical trial with gamma-RV; the gene therapy was licensed to GlaxoSmithKline (GSK) in 2010 and GSK became the financial sponsor of the clinical trial. Other authors disclose no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}